NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read here
See how UMR members are aiding in the fight against the coronavirus here
A new episode of the Amazing Things Podcast is now available! Check it out here.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Tissue Chips and Drug Development: A Conversation with NCAT’s Dr. Lucie Low


Lung on a chip from the Wyss Institute at Harvard University
Credit: Daniel Sone Photography

In this episode of The Amazing Things Podcast, we talk to Dr. Lucie Low about tissue chip technology and its potential to change how we develop and test new drugs. Dr. Low is the Scientific Program Manager of the Tissue Chip for Drug Screening Program at the National Center for Advancing Translational Sciences (NCATS), part of the National Institute of Health.

Approximately 30 percent of promising medications have failed in human clinical trials because they are found to be toxic despite promising preclinical studies in animal models. Additionally, about 60 percent of drug candidates fail due to lack of efficacy. These currently unavoidable facts of the drug development process are one reason why there is so much excitement around tissue chips.